Johnson & Johnson (FRA:JNJ)
Germany
· Delayed Price · Currency is EUR 130.22
-0.10 (-0.08%)
At close: Jun 27, 2025, 10:00 PM CET
Johnson & Johnson Employees
Johnson & Johnson had 138,100 employees as of December 29, 2024. The number of employees increased by 6,200 or 4.70% compared to the previous year.
Employees
138,100
Change (1Y)
6,200
Growth (1Y)
4.70%
Revenue / Employee
€597,179
Profits / Employee
€145,800
Market Cap
312.99B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 29, 2024 | 138,100 | 6,200 | 4.70% |
| Dec 31, 2023 | 131,900 | -20,800 | -13.62% |
| Jan 1, 2023 | 152,700 | 11,000 | 7.76% |
| Jan 2, 2022 | 141,700 | 7,200 | 5.35% |
| Jan 3, 2021 | 134,500 | 2,300 | 1.74% |
| Dec 29, 2019 | Pro | Pro | Pro |
| Dec 30, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Jan 1, 2017 | Pro | Pro | Pro |
| Jan 3, 2016 | Pro | Pro | Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| SAP SE | 109,121 |
| Siemens Aktiengesellschaft | 327,000 |
| Deutsche Telekom AG | 198,194 |
| Allianz SE | 156,626 |
| Rheinmetall AG | 28,539 |
| Siemens Energy AG | 98,000 |
| Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 44,224 |
| Siemens Healthineers AG | 72,000 |
Johnson & Johnson News
- 1 day ago - Johnson & Johnson Is Great. Here's Why You Shouldn't Buy It. - The Motley Fool
- 2 days ago - Tech stocks rally: Semiconductors lead the charge while healthcare stumbles - Forexlive
- 4 days ago - Johnson & Johnson: Undervalued Dividend King With 65% Upside Potential - Seeking Alpha
- 4 days ago - How To Build A $1,000,000 Dividend Portfolio That Could Yield 11%+ In 15 Years - Seeking Alpha
- 4 days ago - Best Dividend Kings: June 2025 - Seeking Alpha
- 5 days ago - Johnson & Johnson reports positive results from Imaavy study - Seeking Alpha
- 5 days ago - IMAAVY™ (nipocalimab-aahu) showed greater sustained disease control versus approved FcRn blockers for generalized myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly published indirect treatment comparison (ITC) - Benzinga
- 5 days ago - IMAAVY™ (nipocalimab-aahu) showed greater sustained disease control versus approved FcRn blockers for generalized myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly published indirect treatment comparison (ITC) - PRNewsWire